Ionis Pharmaceuticals Inc
IONS43.000USD
-0.590-1.35%
Cierre 07/03, 13:00（ET）Cotizaciones retrasadas 15 min
6.84BCap. mercado
PérdidaP/E TTM
Más Datos de Ionis Pharmaceuticals Inc Compañía
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Información de la empresa
Símbolo de cotizaciónIONS
Nombre de la empresaIonis Pharmaceuticals Inc
Fecha de salida a bolsaMay 17, 1991
Fundada en1991
Director ejecutivoDr. Brett P. Monia, Ph.D.
Número de empleados1069
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 17
Dirección2855 Gazelle Court
CiudadCARLSBAD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92010
Teléfono17609319200
Sitio Webhttps://www.ionis.com/
Símbolo de cotizaciónIONS
Fecha de salida a bolsaMay 17, 1991
Fundada en1991
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
32.25K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Desglose de ingresos
Divisa: USDActualizado: mar., 4 de mar
Divisa: USDActualizado: mar., 4 de mar
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Estadísticas de accionistas
Actualizado: jue., 3 de jul
Actualizado: jue., 3 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
67.26%
Investment Advisor/Hedge Fund
28.07%
Hedge Fund
13.12%
Research Firm
2.36%
Private Equity
1.60%
Sovereign Wealth Fund
1.08%
Pension Fund
0.93%
Individual Investor
0.81%
Bank and Trust
0.52%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
787
184.68M
116.03%
+8.73M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
Capital Research Global Investors
10.50M
6.6%
+10.50M
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Nombre
Proporción
ARK Genomic Revolution ETF
3.36%
Tema Neuroscience and Mental Health ETF
2.73%
Capital Group US Small and Mid Cap ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.66%
SPDR S&P Biotech ETF
1.45%
Tema Cardiovascular and Metabolic ETF
1.25%
WisdomTree BioRevolution Fund
1.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Franklin Genomic Advancements ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.61%
Ver más
ARK Genomic Revolution ETF
Proporción3.36%
Tema Neuroscience and Mental Health ETF
Proporción2.73%
Capital Group US Small and Mid Cap ETF
Proporción2.15%
Virtus LifeSci Biotech Products ETF
Proporción1.66%
SPDR S&P Biotech ETF
Proporción1.45%
Tema Cardiovascular and Metabolic ETF
Proporción1.25%
WisdomTree BioRevolution Fund
Proporción1.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.86%
Franklin Genomic Advancements ETF
Proporción0.62%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.61%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
